- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02305862
A High-Resolution Magnetic Resonance Imaging Study to Evaluate the Effect of Rosuvastatin on Carotid Atherosclerotic Plaques
An Open-label, Single-centre Randomized Study Evaluating the Effect of Treatment With Rosuvastatin 5/20mg on Atherosclerotic Disease as Measured by High-Resolution Contrast Enhanced Magnetic Resonance Imaging in Patients With Coronary Artery Disease and Hyperlipideimia
The aim of this study is to assess whether high intensive statin therapy could regress carotid atherosclerotic plaques as determined by High-Resolution Contrast Enhanced Magnetic Resonance imaging (CE-MRI).
Enrolled patients have a baseline CE-MRI examination for screening carotid atherosclerotic plaques and are randomized to either low dose of Rosuvastatin (5mg) group or high dose of Rosuvastatin (20mg) group. After 26 weeks, all patients received CE-MRI examination again and each pair of baseline and follow-up CE-MRI assessments was analyzed in a blinded fashion. Moreover, lipid level and major adverse cardiovascular events are also evaluated during follow-up.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Beijing, China, 100050
- Recruiting
- Beijing Tiantan Hospital, Capital Medical University
-
Contact:
- Qiang Fu, Dr
- Phone Number: 861067096562
- Email: fuqiang66882000@hotmail.com
-
Principal Investigator:
- Buxing Chen, Dr
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
-Patients with coronary artery disease or carotid atherosclerotic plaque or hyperlipideimia or old myocardial infarction
Exclusion Criteria:
- Planning coronary stenting
- Heart failure
- Uncontrolled hypertension(≥200/110mmHg)
- Uncontrolled diabetes mellitus (HbA1C≥9.5%)
- Hepatic insufficiency
- Renal dysfunction
- Cancer
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: low dose group (5mg)
low dose Rosuvastatin
|
drug intervention
|
Experimental: high dose group (20mg)
high dose Rosuvastatin
|
drug intervention
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To evaluate whether 26 weeks of treatment with 5/20mg rosuvastatin results in regression of carotid atherosclerotic plaques as measured by CE-MRI
Time Frame: 26 weeks
|
26 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
major adverse cardiovascular events
Time Frame: 26 weeks
|
26 weeks
|
To evaluate the change in lipid and lipoprotein levels as assessed by percentage change from baseline.
Time Frame: 26 weeks
|
26 weeks
|
To evaluate the change from baseline in liver function (AST/ALT) at 26 weeks
Time Frame: 26 weeks
|
26 weeks
|
To evaluate the change from baseline in renal function (serum creatine) at 26 weeks
Time Frame: 26 weeks
|
26 weeks
|
To evaluate the change from baseline in creatine kinase at 26 weeks
Time Frame: 26 weeks
|
26 weeks
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Metabolic Diseases
- Arterial Occlusive Diseases
- Arteriosclerosis
- Lipid Metabolism Disorders
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antimetabolites
- Anticholesteremic Agents
- Hypolipidemic Agents
- Lipid Regulating Agents
- Hydroxymethylglutaryl-CoA Reductase Inhibitors
- Rosuvastatin Calcium
Other Study ID Numbers
- AMARIROCAP
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Arteriosclerosis
-
Daewoong Pharmaceutical Co. LTD.CompletedArteriosclerosis ObliteransKorea, Republic of
-
Jun-min BaoUnknownArteriosclerosis; ExtremitiesChina
-
Kansai Rosai HospitalAssociation for Establishment of Ebvidence in InterventionsUnknownArteriosclerosis ObliteransJapan
-
GE HealthcareTurku University Hospital; University of Turku; The Finnish Funding Agency for...CompletedArteriosclerosis ObliteransFinland
-
Region Örebro CountyRecruitingCoronary Stenosis | Calcific Coronary ArteriosclerosisSweden
-
Guangzhou Yipinhong Pharmaceutical CO.,LTDUnknownArteriosclerosis ObliteransChina
-
Medtronic CardiovascularCompletedArteriosclerosis of Coronary Artery Bypass GraftCanada, United States
-
Cordis CorporationCompletedCoronary Arteriosclerosis | Angioplasty, Transluminal, Percutaneous Coronary | Peripheral ArteriosclerosisUnited States
-
Johns Hopkins UniversityNorthwestern UniversityCompletedCoronary Artery Disease | Coronary Arteriosclerosis | Coronary Atherosclerosis | Atherosclerosis, Coronary | Arteriosclerosis, CoronaryUnited States
-
University of VermontNational Heart, Lung, and Blood Institute (NHLBI)CompletedHeart Diseases | Cardiovascular Diseases | Coronary Disease | Atherosclerosis | Coronary Arteriosclerosis | Cerebrovascular Accident | Cerebral Arteriosclerosis
Clinical Trials on Rosuvastatin 5mg
-
Wei LiuAstraZeneca; University of Washington; Beijing Clinstech-med consulting Co., LtdUnknownCarotid AtherosclerosisChina
-
Yuhan CorporationLinical KoreaCompletedDiabetes Mellitus and HypercholesterolemiaKorea, Republic of
-
Alvogen KoreaCompletedPrimary HypercholesterolemiaKorea, Republic of
-
Odense University HospitalCompleted
-
Odense University HospitalCompletedAtherosclerosis | Endothelial DysfunctionDenmark
-
Korea University Anam HospitalSamjin Pharmaceutical Co., Ltd.UnknownCardiovascular Diseases | Coronary Artery Disease | Coronary DiseaseKorea, Republic of
-
Kiyuk Chang, MD,PhDRecruitingMyocardial Infarction | Statin Adverse Reaction | HMG-CoA Reductase Inhibitor ToxicityKorea, Republic of
-
Hanlim Pharm. Co., Ltd.CompletedPrimary Hypercholesterolemia
-
University of Kansas Medical CenterEli Lilly and Company; Kowa Pharmaceuticals America, Inc.CompletedHypercholesterolemiaUnited States
-
Eisai Co., Ltd.Completed